We have developed a structural mass action kinetic model for P-gp mediated transport (Tran et al., 2005; Acharya et al., 2008; Agnani et al., 2011; Lumen et al., 2013 ). The structural model uses the generally accepted mass action reactions for P-gp binding and efflux (equation 1), along with the known structural parameters for P-gp and the cells, then solves the non-linear differential equations of the mass-action reactions to fit the kinetic parameters. Unlike the Michaelis-Menten approach, there is no need for steady-state assumptions, since they are not required to execute this model (Bentz et al., 2005) . In this work we have investigated whether the elementary rate constants (k 1 , k r and k 2 ) obtained by our mass action kinetic model can be extrapolated to Caco-2 cells. We found that the elementary rate constants are very similar between the two cell lines. This suggests that these parameters are fairly system independent.
In addition, our results provided kinetic support for the presence of basolateral uptake transporters for digoxin and loperamide in Caco-2 cells, as shown previously for MDCKII-hMDR1-NKI and MDCKII-hMDR1-NIH cells (Lumen et al, 2013) . This means that for these compounds, the most essential assumption of the derivation of the Michalis-Menten steady state equations, that both substrate and inhibitor interact with only P-gp, is not met in these cell lines.
Finally, since our structural mass action kinetic model also derives efflux active P-gp levels. Our companion paper (Meng et al., 2016b) shows that there can be a substantial difference (~10 fold)
between efflux active and total plasma membrane P-gp levels, depending on the morphology of the microvilli in the in vitro system. All of these simulations can be turned into a PBPK model within the MathWorks SimBiology program. SimBiology can also access all of the MATLAB functions needed to execute the calculations in our model.
Materials and Methods
Loperamide, quinidine and digoxin were from Sigma (St. Louis, MO); amprenavir and GF120918
were from GlaxoSmithKline. Total RNA from confluent MDCKII-hMDR1-NKI and Caco-2 cell monolayers was extracted using SV 96 Total RNA Isolation System according to the manufacturer's instructions.
cDNA was prepared by performing reverse transcription using an oligo (dT) [12] [13] [14] [15] [16] [17] [18] 
Caco-2 Cell Monolayer Culture and Transport Study
For the P-gp mediated transport experiments, cells were seeded on polycarbonate membrane inserts at a density of 2.5 × 10 5 / cm 2 and maintained for 21 days in complete medium; the medium was changed every 2-3 days. After 21 days the monolayer integrity was determined by measuring the TEER using across the confluent cell monolayers over 6 hours was measured in both directions, i.e. apical to basolateral (A>B) and basolateral to apical (B>A) in the presence and absence of GF120918. For incubations in the presence of GF120918, the inhibitor was added to both chambers. In addition, 100 µM lucifer yellow was added to donor chamber to monitor cell monolayer integrity. At the indicated time points, 25 µL samples were taken from both these chambers and counted by TopCount Model 19912. Lucifer yellow concentrations were determined using a SpectraMax Gemini fluorescence microplate reader at wavelengths of λ ex 430 nm and λ em 538 nm.
Kinetic Model of Transport across a Confluent Cell Monolayer
The basic structural mass action kinetic model is depicted in Fig.1 and Eq 1, 2A and 2B. Important components of the model are: passive permeability across the lipid bilayers obtained in the presence of GF120918; partitioning of substrates into the membranes; active transport by P-gp and by other transporters (Tran et al., 2005) . Active transport by P-gp occurs uni-directionally, with substrate binding to a site on P-gp within the apical membrane inner monolayer and with efflux into the apical chamber. The simplest Michaelis-Menten mass action reaction to model active P-gp transport is shown in Equation 1. In this "P-gp only" model, the elementary rate constants are simultaneously fitted to mass action equations for P-gp mediated transport and passive permeability. Importantly, the P-gp surface density is an explicit mass action variable and fitted along with other parameters. The elementary rate constants define the binding constant of the substrate to P-gp from the membrane (K C =k 1 /k r ), not the cytosol. The on rate constant, efflux active P-gp surface density, efflux rate constant and partition coefficient together give the molecular K m =((k r +k 2 )/k 1 ) * K PC , where K PC is the partition coefficient of the drug into the cytosolic lipid inner monolayer (Bentz et al., 2005) and V max =k 2 T(0) for P-gp transport. Our kinetic analysis can use transport data from multiple initial drug
concentrations and time points until the final steady state is approached, which is when concentrations in donor and receiver chamber no longer change, to fit the elementary rate constants for each new drug.
In addition, our model can kinetically detect the presence of other transporters contributing to the total P-gp mediated transport (Acharya et al., 2008) . We used facilitated transporter models for additional transporters to allow the mass action kinetics a degree of freedom to determine transport directionality based on the fits. According to our previous data, the fits are consistent with a bidirectional facilitated transporter or an active (uni-directional) uptake transporter, although a bidirectional facilitated transporter fitted the data somewhat better (Agnani et al., 2011) . Since the true identity of these transporters is unknown, each transporter was characterized by a single bidirectional first-order kinetic clearance (k B ). They are denoted as AT, for apical uptake transporter, and BT, for basolateral uptake transporter, Eq (2).
It is possible that more than one transporter is involved at these membranes. In that case, we would be fitting some weighted average. Importantly, P-gp mediated transport was not estimated by simply subtracting the transport in the presence of GF120918 from the total transport, which does not take back flow into consideration (Tran et al., 2005) . Instead, passive permeability coefficients over time were included within the mass action differential equations and fixed by the time-dependent experiments in the presence of GF120918.
Lipid bilayer partition coefficients are used to define the free concentrations within the aqueous compartment that is contained by the lipid monolayer (Tran et al., 2005; Lumen et al., 2013) . Partition coefficients were fixed at the values shown in Table 1 . The differential equations were solved in MATLAB 2014b using the ODE23s solver.
Data analysis using particle swarm
The particle swarm program was used to fit the elementary rate parameters for our data sets. All the applicable data is fitted simultaneously. All kinetic parameters were free to range during the fitting.
Each fitted parameter is shown as the average and standard deviation of 6 independent fittings. The "goodness of fit" to a particular drug data set was quantified by the coefficient of variation (CV) calculated between model simulations and the experimentally measured kinetic data. T(0) and k 1 were fitted as a consensus for all the drug data, while k r , k 2 and k B were refitted as drug dependent ( Previously, we found that the efflux active P-gp surface density T(0) in confluent MDCKII-hMDR1-NKI cell monolayers was independent of which drug was being transported. This is as expected since the same MDCK cell line was used to measure transport of each drug, and is a benchmark of our fitting approach (Tran et al., 2005; Agnani et al., 2011) . The association rate constant k 1 was also drug independent, which was not required, and was on the order of the maximal diffusion rate of a drug like compound through a lipid bilayer (Tran et al., 2005) . This is consistent with the fact that the P-gp binding site is large compared to the molecular size of the drugs we studied (Aller et al., 2009 ). The small standard deviations of the drug independent T(0) and k 1 values found here for Caco-2 cells (Table 1A) suggest that a good consensus fit was obtained for these parameters by simultaneously fitting transport data from the four drugs used in this work. As anticipated, T(0) is compound independent as the same Caco-2 cell line is used for each drug. The k 1 in Caco-2 cells was also drug independent and large, as was the case for the MDCK-MDR1-NKI cells, with an absolute value very close to that found in MDCK-hMDR1-NKI cells (Table 1B) . The upper and lower bound for k 1 and efflux active P-gp surface density were the same as in Agnani et al. (2011) .
Fitting the drug dependent values: k r , k 2 and k B .
We next fitted the drug dependent kinetic parameters k r and k 2 . T(0) and k 1 were fixed at their consensus values (Table 1A ) and k r and k 2 were obtained in 6 independent replicate fits for each drug.
For this first round of fitting, we assumed that no other transporter was involved in transcellular transport. Then the data sets were refitted to 3 scenarios, allowing a bidirectional basolateral transporter, a bidirectional apical transporter, or both in the model. The assessment of whether a basolateral or apical transporter plays a role is then based on improvement in the fits (Table 3 ). The goodness of fit is based on the coefficient of variation (CV) between data and fit. Our criterion for a good fit is a CV ≤ 0.03 (Tran et al., 2005) . If incorporation of an additional transporter results in a 25% improvement in the CV (regardless of the initial CV), then the additional transporter is considered to play a kinetically significant role. Amprenavir and quinidine transport data was well fitted with just k r and k 2 . The CV for the fit to the amprenavir and quinidine data was 0.028 and 0.019, respectively (Table 3) . No significant improvement was observed in the fits by adding additional uptake transporters in the model. These two compounds do not show any kinetic need for other uptake transporters. The symbols in Figure 2A and 2B show the experimental data for transport of 2µM amprenavir and 1µM quinidine in both A>B and B>A directions. The solid lines indicate the fits to the data, using the kinetic parameter values from Table 1A .
For digoxin and loperamide we found that the CV improved by 89% and 30% respectively when a basolateral uptake transporter was allowed in the model (Table 3 ). The symbols in Figure 3A show the experimental data for transport of 1 µM digoxin in the B>A direction. The dotted lines show the best fit to the data when only P-gp is incorporated in the model (kinetic values for P-gp from Table 1A ).
There is a substantial underestimate of the amount of digoxin transported. Without a basolateral uptake transporter the only way for drug to get into the cells according to the model is via passive permeability. It is clear from the fits that not enough loperamide and digoxin was able to enter the
cells by passive permeability alone to be adequately effluxed to the apical chamber to fit the data. With the added basolateral uptake transporter very good fits to the data were obtained.
It is worth noting that in contrast to the MDCKII-hMDR1-NKI cells, no significant improvement in CV was seen for digoxin with addition of an apical transporter in the current study (Table 3) . This is likely due to the much shorter incubation time in this study (6 hours vs 18 hours stitched for the MDCKII-hMDR1-NKI cells) such that back transport from apical to basolateral compartment is insignificant here (Acharya et al., 2008; Lumen et al., 2013) . Similar results were obtained for loperamide ( Figure 3B ), but the effect of the basolateral uptake transporter is smaller, for reasons that are unclear at this time.
The values for k r and k 2 are very similar for Caco-2 cells (Table 1A) and MDCK-MDR1-NKI cells (Table 1B) . In both cell lines, the "P-gp only" model is sufficient for amprenavir and quinidine, but incorporation of a basolateral uptake transporter was required for good fits with both digoxin and loperamide.
The efflux active P-gp surface density was 4.5 ± 1.3 fold greater in the MDCK-MDR1-NKI cells than in Caco-2 cells. We measured P-gp mRNA expression in MDCKII-hMDR1-NKI and Caco-2 cells by quantitative RT-PCR. Table 2 shows that the P-gp mRNA expression level was about 7 fold higher in MDCKII-hMDR1-NKI than in Caco-2 cells. This is consistent with the higher efflux active P-gp surface density in these cells.
Discussion
Mechanistic PBPK models of transporter based DDI data ideally use transporter specific and system independent in vitro kinetic parameters for transport and transport inhibition as well as scaling factors for active transporter levels (Huang et al., 2013; Jones et al., 2015) . In reality, however, these PBPK models currently often require compound specific scaling factors to generate a good fit to the data and thus lose mechanistic value. The physical nature of these compound specific scaling factors is generally not understood.
In the Michaelis-Menten steady state analysis, the mass action kinetic equation for transport can be solved algebraically when considering initial rate data only. In the structurally based mass action kinetic model we developed for P-gp transport, the kinetic analysis is not limited to initial rates, but in fact relies on approaching a final steady state for transport, i.e. until the concentrations of drug in donor and receiver chamber no longer change. In this case the mass action kinetic equations for transport are solved by numerical integration coupled with Global Optimization to obtain the elementary rate constants governing P-gp transport as well as the efflux active P-gp surface density. This model has been validated using transport data across confluent MDCKII-hMDR1-NKI cells (Agnani et al., 2011) .
When Michaelis-Menten steady state kinetics are applied to P-gp mediated transport across polarized cells it is typically assumed that P-gp is the only transporter involved in the transport process. processes. In other words, the K m value becomes system dependent and translation to in vivo is unclear, unless the contribution of the other transport process is explicitly recognized. Our ultimate goal is to obtain robust system-independent kinetic parameters for P-gp mediated drug transport in vitro, which can be used in PBPK models, in combination with scaled values for efflux active (not total) transporter levels to predict drug concentrations in tissues.
In order to determine if the fitted elementary rate constants from the structural model can be directly extrapolated to other systems, we determined these rate constants in a second cell line, Caco-2. As is shown in Tables 1A and 1B, rate constants of the uptake clearance values for digoxin and loperamide between the two cell lines is meaningless.
It has been claimed recently that the unstirred water layer (UWL) should be accounted for when measuring transport kinetics using cultured cell systems. Otherwise, the apparent affinity of the substrate to the transporters may be underestimated (Shibayama et al., 2015) . In our model, since the passive permeability was fitted when P-gp and the basolateral uptake transporter are fully inhibited by GF120918 (Tran et al., 2005) , any effect of UWL will be included in the passive permeability coefficient. As a result, our fitted elementary rate constants for P-gp active transport or BT clearance
lower P-gp mRNA expression was observed in Caco-2 cells compared to MDCKII-hMDR1-NKI cells (Meng et al., 2016b) .
However, in our companion paper, we found that amounts of P-gp protein per transwell were effectively the same for both cell lines (Meng et al., 2016b) . It was possible that the level of total P-gp is the same in both cell lines, but that a greater fraction of Pgp on MDCKII-hMDR1-NKI cells is efflux active due to a difference in morphology of microvilli between the two cell lines (Tran et al., 2005) .
By electron microscopy, Caco-2 cells possess longer and more densely packed microvilli than MDCK cells (Butor et al., 1992; Gill et al., 2008; Nicolaou et al., 2012) . We have speculated previously that for the packed microvilli, like Caco-2 cells, the efflux into the apical chamber happens only from P-gp at the tips of the microvilli (Tran et al., 2005) . Drug molecules released from P-gp at the base of a microvillus would randomly diffuse through the aqueous space between microvilli, until most partition again into the apical membrane, as though the molecule had never been effluxed. In this case the efflux active P-gp is a fraction of the total plasma membrane P-gp. The fraction of efflux active Pgp will
passive permeability of less than 300-350 nm/s that our kinetic analysis could identify the kinetic need for a basolateral uptake transporter. For compounds with lower passive permeabilities, we have kinetically identified that a basolateral uptake transporter is contributing to the overall transport kinetics of several P-gp substrates in MDCKII-hMDR1-NKI, MDCKII-hMDR1-NIH and two Caco-2 cell lines (Lumen et. al, 2013 ; this work). Thus for these compounds the Michaelis-Menten K m is a convolution of binding to two transporters and is therefore system dependent. Cartoon of polarized cells, with the apical membrane on top and the basolateral membrane on the bottom. Passive permeability occurs in both directions. P-gp expressed on the apical membrane transports substrate from the inner apical membrane monolayer into the apical chamber. Substrate binds to P-gp with an association rate constant k 1 , dissociates from P-gp back into apical membrane with an off rate constant k r , and effluxes from membrane to apical chamber with an efflux rate constant Table 1A . 
